Clinical trial NCT00838721: Evaluation of Pascal Laser Trabeculoplaty
Official title: Prospective Evaluation of the Efficacy of Pascal Trabeculoplasty: A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Open Angle Glaucoma
Ocular Hypertension
Keywords: Open Angle Glaucoma
Ocular Hypertension
Laser Trabeculoplasty
Lead sponsor: Santa Clara Valley Health & Hospital System
Sponsor class: OTHER
Collaborators: name: OptiMedica Corporation
First posted: 2009-02-06
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Laser Trabeculoplasty has been shown to be effective in lowering intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG). Although initially demonstrated with the Argon laser (ALT), several other laser systems have also been employed with comparable efficacy. Recently, Selective Laser Trabeculoplasty (SLT) has been shown to lower intraocular pressure comparable to ALT. The advantage of SLT is that the target eye structure, the trabecular meshwork, remains intact with minimal damage at the cellular level. In contrast, ALT lowers IOP at the expense of scarring of the trabecular meshwork. The purpose of this study is to evaluate the efficacy of lowering IOP with Pascal Laser Trabeculoplasty (PLT) employing reduced energy levels compared to ALT and a computer guided pattern of laser treatment applications.


Eligibility criteria: Inclusion Criteria:

1. Otherwise healthy males and females, older than 18 years of age with two (2) sighted eyes
2. Have OAG, PXG, or combined mechanism glaucoma - as long as their angles are open
3. Have uncontrolled IOP (\>24mmHg); or controlled with Medicine(s)
4. If on medical treatment, have undergone a washout period of at least one month prior to Pascal treatment
5. Able and willing to comply with the treatment/follow-up schedule and requirements;
6. Able to provide written informed consent

Exclusion Criteria:

1. Pregnant, intending to become pregnant during course of study, less than 3 months postpartum or less than 6 weeks after completion of breastfeeding
2. Have an advanced visual field defect within 10° of fixation
3. Have had previous glaucoma surgery, except for peripheral iridotomy
4. Have corneal disease obviating the use of corneal applanation for a reliable IOP measurement, or would cause difficulty in viewing the TM by means of gonioscopic lens
5. Using systemic steroids
6. Participation in a study of another device or drug within 3 month prior to study enrollment or during this study, and as per the Investigator's careful discretion, as long as not contradictory to any of the above criteria
7. Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research study
8. No concomitant use of IOP lowering medicine (Group 1)
9. No co-existing ocular pathology with the exception of Cataract.

Primary outcomes:
measure: intraocular pressure
timeFrame: 1 week, 1 month, 3 months, 6 months, 9 months and 1 year after treatment
Secondary outcomes:
Other outcomes:
Locations:
city: San Jose
country: United States
facility: Santa Clara Valley Medical Center
state: California
Study officials:
affiliation: Santa Clara Valley Medical Center
name: Christopher J Engelman, MD
role: PRINCIPAL_INVESTIGATOR
References: